Anticancer Prodrug
A special issue of Pharmaceutics (ISSN 1999-4923).
Deadline for manuscript submissions: closed (30 April 2019)
Special Issue Editor
Interests: vitamin E; tocopherols; tocotrienols; oxidative stress; cancer; pediatrics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
I would like to invite you to contribute an article to upcoming special issue of Pharmaceutics focusing on the development and clinical potential of anticancer prodrugs. The general scope of this special issue is outlined below. Anticancer prodrugs can broadly be defined as nontoxic agents selectively activated to chemotherapeutic drugs in cancer cells, tumors or the tumor microenvironment. Anticancer prodrugs can also serve as adjuvants to enhance or beneficially affect another cancer therapy, e.g., radiation therapy. As a branch of precision oncology, the clinical application of anticancer prodrugs holds the promise of individualized treatment with the maximum therapeutic response with minimum side-effects. Anticancer prodrugs can target generalized molecular alterations resulting from tumor hypoxia and increased oxidative stress or, precise alterations resulting from perturbations in signal transduction pathways. The application of “omics” technologies, such as genomics and proteomics, to characterize tumors is rapidly advancing the discovery of novel cancer biomarkers. These novel biomarkers can also serve as targets for anticancer prodrugs.
Prof. William L. Stone
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anticancer
- prodrugs
- chemotherapy
- personalized medicine
- tumors
- oxidative stress
- hypoxia
- proteomics
- genomics
